New technology transforming vaccine development through faster viral detection

Could we finally have a faster, more objective analytical tool to rapidly measure viral infectivity for vaccine development and production? Scientists and bioengineers at Thermo Fisher Scientific and LumaCyte believe we do. This peer reviewed work has been published on September 12th in the prestigious journal, Vaccine, by Elsevier, detailing how LumaCyte’s RadianceTM instrument, based on Laser Force Cytology (LFC), offers researchers the ability to rapidly analyze viral vaccines to speed development and production and ensure their effectiveness. Many viral vaccines use live infectious viruses to generate an immune response that later protects vaccinated individuals from a new infection with the same or similar virus. Thus, the measurement of infectious virus concentration is critical for vaccine safety and efficacy and is used throughout R&D, biomanufacturing, release testing, and clinical trials. Current techniques for measuring viral infectivity are generally slow, labor-intensive and difficult to standardize, which often creates a bottleneck in the development...